Xenios AG, a company of the Fresenius Medical Care Group, reports that it has seen a significant growth in demand for its extracorporeal membrane oxygenation (ECMO) devices, which can be used for the treatment of patients who develop severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 infection.
\nJ\u00fcrgen B\u00f6hm, CMO of Xenios, explained that for critically ill COVID-19 patients with acute lung failure and refractory hypoxemia \u2013 despite use of standard therapy \u2013 \u201cour treatment often remains the last therapeutic option and has been a lifesaver for many patients\u201d.
\nXenios\u2019s ECMO therapy bypasses the function of the lungs. The patient\u2019s blood is freed from carbon dioxide outside the body and enriched with oxygen. The lungs are thus given time to heal. Because of the increase of critically ill COVID-19 patients, more physicians are opting for ECMO therapy, and thus the increase in demand for Xenios\u2019s ECMO devices.
\nTo meet the demand, the company has increased production of its ECMO devices. \u201cWe have put many measures in place to maximize the utilization of our capacity to manufacture ECMO devices as well as patient kits. Our biggest challenge right now is the availability of specific components for our products,\u201d said Andreas Terpin, CEO of Xenios.
\nFor more information, visit: www.xenios-ag.com<\/link>\n<\/p>\n
Supplier:<\/strong> [No title]
\nWebsite:<\/strong> <\/a><\/p>\n